These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 30513252)

  • 1. Antibody persistence in pre-school children after hexavalent vaccine infant primary and booster administration.
    Madhi SA; López P; Zambrano B; Jordanov E; B'Chir S; Noriega F; Feroldi E
    Hum Vaccin Immunother; 2019; 15(3):658-668. PubMed ID: 30513252
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Randomized Controlled Study of a Fully Liquid DTaP-IPV-HB-PRP-T Hexavalent Vaccine for Primary and Booster Vaccinations of Healthy Infants and Toddlers in Latin America.
    López P; Arguedas Mohs A; Abdelnour Vásquez A; Consuelo-Miranda M; Feroldi E; Noriega F; Jordanov E; B Chir S; Zambrano B
    Pediatr Infect Dis J; 2017 Nov; 36(11):e272-e282. PubMed ID: 28719500
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antibody persistence after a primary series of a new DTaP-IPV-Hep B-PRP-T combined vaccine or separate DTaP-IPV//PRP-T and hepatitis B vaccines at 2, 4, and 6 months of age and the effect of a subsequent DTaP-IPV//PRP-T booster vaccination at 18 months of age in healthy Argentinean infants.
    Tregnaghi M; Zambrano B; Santos-Lima E
    Pediatr Infect Dis J; 2012 Jan; 31(1):e24-30. PubMed ID: 22157567
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Concomitant administration of a fully liquid ready-to-use DTaP-IPV-HB-PRP-T hexavalent vaccine with a meningococcal ACWY conjugate vaccine in toddlers.
    Vesikari T; Borrow R; Da Costa X; Thomas S; Eymin C; Boisnard F; Lockhart S
    Vaccine; 2018 Dec; 36(52):8019-8027. PubMed ID: 30471953
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Persistence of hepatitis B immune memory until 9-10 years of age following hepatitis B vaccination at birth and DTaP-IPV-HB-PRP∼T vaccination at 2, 4 and 6 months.
    Kosalaraksa P; Chokephaibulkit K; Benjaponpitak S; Pancharoen C; Chuenkitmongkol S; B'Chir S; Da Costa X; Vidor E
    Hum Vaccin Immunother; 2018 May; 14(5):1257-1265. PubMed ID: 29333947
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Concomitant administration of a fully liquid, ready-to-use DTaP-IPV-HB-PRP-T hexavalent vaccine with a meningococcal serogroup C conjugate vaccine in infants.
    Vesikari T; Borrow R; Da Costa X; Richard P; Eymin C; Boisnard F; Lockhart S
    Vaccine; 2017 Jan; 35(3):452-458. PubMed ID: 27939054
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunogenicity and Safety of Primary and Booster Vaccinations of a Fully Liquid DTaP-IPV-HB-PRP-T Hexavalent Vaccine in Healthy Infants and Toddlers in Germany and the Czech Republic.
    Prymula R; Kieninger D; Feroldi E; Jordanov E; B'Chir S; DaCosta X
    Pediatr Infect Dis J; 2018 Aug; 37(8):823-830. PubMed ID: 29762363
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of a Hexavalent-Pentavalent-Hexavalent Infant Primary Vaccination Series Followed by a Pentavalent Booster Vaccine in Healthy Infants and Toddlers.
    Martinón-Torres F; Diez-Domingo J; Feroldi E; Jordanov E; B'Chir S; Da Costa X
    Pediatr Infect Dis J; 2019 Mar; 38(3):317-322. PubMed ID: 30408001
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibody persistence and booster vaccination of a fully liquid hexavalent vaccine coadministered with measles/mumps/rubella and varicella vaccines at 15-18 months of age in healthy South African infants.
    Madhi SA; Koen A; Cutland C; Groome M; Santos-Lima E
    Pediatr Infect Dis J; 2013 Aug; 32(8):889-97. PubMed ID: 23538523
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A fully liquid DTaP-IPV-Hep B-PRP-T hexavalent vaccine for primary and booster vaccination of healthy Mexican children.
    Aquino AG; Brito MG; Doniz CE; Herrera JF; Macias M; Zambrano B; Plennevaux E; Santos-Lima E
    Vaccine; 2012 Oct; 30(45):6492-500. PubMed ID: 22863658
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunogenicity and safety following primary and booster vaccination with a hexavalent diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated poliovirus and Haemophilus influenzae type b vaccine: a randomized trial in the United States.
    Klein NP; Abu-Elyazeed R; Cheuvart B; Janssens W; Mesaros N
    Hum Vaccin Immunother; 2019; 15(4):809-821. PubMed ID: 30444673
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of hepatitis B surface antibody levels induced by the pentavalent DTwP-HB-Hib versus the hexavalent DTaP-HB-Hib-IPV vaccine, administered to infants at 2, 4, 6, and 18 months of age, following monovalent hepatitis B vaccination at birth.
    Posuwan N; Wanlapakorn N; Vongpunsawad S; Sintusek P; Leuridan E; Van Damme P; Poovorawan Y
    Vaccine; 2020 Feb; 38(7):1643-1651. PubMed ID: 31948817
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunological persistence in 5 y olds previously vaccinated with hexavalent DTPa-HBV-IPV/Hib at 3, 5, and 11 months of age.
    Silfverdal SA; Assudani D; Kuriyakose S; Van Der Meeren O
    Hum Vaccin Immunother; 2014; 10(10):2795-8. PubMed ID: 25483640
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunogenicity and Safety of a Hexavalent DTwP-IPV-HB-PRP~T Vaccine Versus Separate DTwP-HB-PRP~T, bOPV, and IPV Vaccines Administered at 2, 4, 6 Months of Age Concomitantly With Rotavirus and Pneumococcal Conjugate Vaccines in Healthy Infants in Thailand.
    Sanchez L; Rungmaitree S; Kosalaraksa P; Jantarabenjakul W; Leclercq J; Yaiprayoon Y; Midde VJ; Varghese K; Mangarule S; Noriega F
    Pediatr Infect Dis J; 2023 Aug; 42(8):711-718. PubMed ID: 37257121
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antibody persistence at 18-20 months of age and safety and immunogenicity of a booster dose of a combined DTaP-IPV//PRP∼T vaccine compared to separate vaccines (DTaP, PRP∼T and IPV) following primary vaccination of healthy infants in the People's Republic of China.
    Li RC; Li FX; Li YP; Hou QM; Li CG; Li YN; Chen FS; Hu XZ; Su WB; Zhang SM; Fang HH; Ye Q; Zeng TD; Liu TX; Li XB; Huang YN; Deng ML; Zhang YP; Ortiz E
    Vaccine; 2011 Nov; 29(50):9337-44. PubMed ID: 22001281
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term immunogenicity assessment of a DTaP-IPV//PRP-T vaccine given at 2, 4, 6 and 18-19 months of age, and immunogenicity and safety of a DTaP-IPV vaccine given as a booster dose at 4 to 6 years of age in Thai children.
    Pancharoen C; Chotpitayasunondh T; Chuenkitmongkol S; Ortiz E
    Southeast Asian J Trop Med Public Health; 2012 May; 43(3):687-98. PubMed ID: 23077849
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Persistence of Hepatitis B Immune Memory Until 6 Years of Age Following Hexavalent DTaP-IPV-HB-PRP~T Vaccination in a 3-, 5- and 11- to 12-month Schedule and Response to a Subsequent Hepatitis B Challenge Vaccination.
    Virta M; Soininen A; Patel DM; Petit C; Tabar C; Lyabis O
    Pediatr Infect Dis J; 2021 Jan; 40(1):e28-e30. PubMed ID: 33284254
    [TBL] [Abstract][Full Text] [Related]  

  • 18. One-year post-primary antibody persistence and booster immune response to a DTaP-IPV//PRP~T vaccine (Pentaxim) given at 18 - 19 months of age in South African children primed at 6, 10 and 14 weeks of age with the same vaccine.
    Madhi SA; Cutland C; Jones S; Groome M; Ortiz E
    S Afr Med J; 2011 Nov; 101(12):879-83. PubMed ID: 22273029
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antibody persistence to diphtheria toxoid, tetanus toxoid,
    Wanlapakorn N; Sarawanangkoor N; Srimuan D; Thatsanathorn T; Thongmee T; Poovorawan Y
    Hum Vaccin Immunother; 2024 Dec; 20(1):2352909. PubMed ID: 38752802
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunogenicity and safety of a new hexavalent vaccine (DTaP5-IPV-HB-Hib) administered in a mixed primary series schedule with a pentavalent vaccine (DTaP5-IPV-Hib).
    Martinón-Torres F; Boisnard F; Thomas S; Sadorge C; Borrow R;
    Vaccine; 2017 Jun; 35(30):3764-3772. PubMed ID: 28583305
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.